The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.
Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.
With drugs treating rare diseases priced at sky-high levels, can the healthcare system shoulder the financial burden they impose?
With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.
The neurology space is gearing up to shake free of its decade-long stagnancy, with sector leaders and runners-up alike angling to push the boundaries. What that means: Imminent advances in genetic sequencing, targeted treatments and diagnostics, all designed to get to the biological root of neurological disorders. Rebecca Mayer Knutsen explains
Vaccines are in vogue and practically taunting pharma with the potential of blockbuster price tags. But while big companies reign in the sector—largely due to cost- and resource-related barriers of entry—a handful of smaller players are taking a stab at creating vaccines for a narrowing field of unmet diseases, like RSV and C. diff. Rebecca Mayer Knutsen reports
From hormone-replacement therapies to super-effective breast-cancer drugs to the so-called female Viagra, innovation within the women's health category has accelerated in recent months.
While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen outlines the potential threats and solutions
The respiratory field, in which several launches are under way, is branching out, from long-time dominant fixed-dose combinations to a therapeutic arsenal that includes biologics and gene therapy. Rebecca Mayer Knutsen investigates the innovation and the intrigue
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Creative partners should push pharma clients to tell better stories
- Retaining talent: How pharma can compete with Google